

EPIX MEDICAL INC
Form 8-K
December 17, 2003

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **December 16, 2003**

EPIX Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-21863

04-3030815

Edgar Filing: EPIX MEDICAL INC - Form 8-K

(State or other
jurisdiction of
incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

**71 Rogers Street
Cambridge, Massachusetts 02142**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(617) 250-6000**

Item 5. Other Events.

On December 16, 2003, Epix Medical, Inc. issued a press release announcing that it has submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for MS-325, a contrast agent designed specifically for vascular imaging with magnetic resonance angiography (MRA). MS-325 is being co-developed by EPIX and Schering AG, Germany. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 7. Financial Statements and Exhibits.

(c) The following exhibits are furnished with this report:

Exhibit Number	Description
99.1	Press Release dated December 16, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EPIX Medical, Inc.
(Registrant)

Date: December 16, 2003

/s/

Peyton J. Marshall
Peyton J. Marshall
*Senior Vice-President,
Finance and Administration,
Chief Financial Officer*